Welcome to two world-class courses on PK/PD
Introduction to Quantitative Pharmacology and PK/PD,
September 10-11 2014, Munich, Germany
The industry lack people able to design, carry out, and analyze in vivo
experiments to build PK/PD models for subsequent study design and
extrapolate these data across preclinical species and into man. All
pharma companies are searching for people with PK/PD skills.
This course aims to give the course participants confidence and
encouragement to have a go at PK/PD and to build relationships between
bioscience, medicinal chemistry, DMPK, and related scientific
disciplines. The programme is comprised of lectures, group exercises
with discussions combined with PK/PD simulations using Maxsim2.
For more information and registration:
http://www.lakemedelsakademin.se/munich2014
21st Intermediate Workshop on PK/PD Data Analysis:
A four-day Course Using WinNonlin,
October 20-23 2014, Rome, Italy
This intermediate level workshop provides an interface between the
numerical analysis of PK and PD data and physiological concepts. Based
on concepts provided by the lecturers, participants will apply this
information to the appropriate modeling package (WinNonlin) in hands-on
exercises.
The workshop is intended for individuals engaged in the pharmaceutical
industry, regulatory agencies, contract research companies and
universities and for others who want to learn the aspects of model
fitting.
For more information and registration:
http://www.lakemedelsakademin.se/21st
http://www.lakemedelsakademin.se/21st
With kind regards,
Annica Flodin, Project Administrator
Swedish Academy of Pharmaceutical Sciences
Postal Address: P.O. Box 1136, SE-111 81 Stockholm, Sweden
Visiting Address: Wallingatan 26A
Phone +46(0)8 723 50 40
Telefax +46(0)8 20 55 11
www.lakemedelsakademin.se http://www.lakemedelsakademin.se/
****************************************************************************
Detta e-mail har blivit undersökt av http://www.comendo.com
This e-mail has been scanned for viruses by http://www.comendo.com
****************************************************************************